- Home
- ZLAB vs TFPM Comparison
ZLAB vs TFPM Comparison
Compare ZLAB & TFPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- TFPM
- Stock Information
- Founded
- ZLAB 2013
- TFPM 2016
- Country
- ZLAB China
- TFPM Canada
- Employees
- ZLAB N/A
- TFPM N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- TFPM Precious Metals
- Sector
- ZLAB Health Care
- TFPM Industrials
- Exchange
- ZLAB Nasdaq
- TFPM Nasdaq
- Market Cap
- ZLAB 3.0B
- TFPM 3.3B
- IPO Year
- ZLAB 2017
- TFPM N/A
- Fundamental
- Price
- ZLAB $26.85
- TFPM $16.16
- Analyst Decision
- ZLAB Strong Buy
- TFPM Strong Buy
- Analyst Count
- ZLAB 4
- TFPM 4
- Target Price
- ZLAB $52.50
- TFPM $20.50
- AVG Volume (30 Days)
- ZLAB 960.6K
- TFPM 233.2K
- Earning Date
- ZLAB 11-12-2024
- TFPM 01-01-0001
- Dividend Yield
- ZLAB N/A
- TFPM 1.36%
- EPS Growth
- ZLAB N/A
- TFPM N/A
- EPS
- ZLAB N/A
- TFPM N/A
- Revenue
- ZLAB $355,748,000.00
- TFPM $246,517,000.00
- Revenue This Year
- ZLAB $48.50
- TFPM $33.62
- Revenue Next Year
- ZLAB $47.37
- TFPM $11.43
- P/E Ratio
- ZLAB N/A
- TFPM N/A
- Revenue Growth
- ZLAB 35.01
- TFPM 25.66
- 52 Week Low
- ZLAB $13.48
- TFPM $11.75
- 52 Week High
- ZLAB $36.60
- TFPM $18.88
- Technical
- Relative Strength Index (RSI)
- ZLAB 45.71
- TFPM 42.62
- Support Level
- ZLAB $25.85
- TFPM $16.00
- Resistance Level
- ZLAB $29.87
- TFPM $17.01
- Average True Range (ATR)
- ZLAB 1.05
- TFPM 0.34
- MACD
- ZLAB -0.18
- TFPM -0.04
- Stochastic Oscillator
- ZLAB 21.98
- TFPM 28.23
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About TFPM Triple Flag Precious Metals Corp.
Triple Flag Precious Metals Corp is a precious-metals-focused streaming and royalty company. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, and the United States.